Analysts Set Expectations for Immunic FY2026 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Equities researchers at William Blair issued their FY2026 earnings per share (EPS) estimates for Immunic in a research report issued to clients and investors on Monday, March 24th. William Blair analyst M. Minter forecasts that the company will post earnings per share of ($0.98) for the year. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. William Blair also issued estimates for Immunic’s FY2027 earnings at ($0.83) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at $0.96 EPS.

A number of other equities analysts also recently weighed in on IMUX. D. Boral Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Immunic in a report on Wednesday, February 26th. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Immunic in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $12.67.

Immunic Trading Up 3.3 %

Shares of Immunic stock opened at $1.24 on Thursday. Immunic has a 1 year low of $0.92 and a 1 year high of $2.11. The company has a market cap of $111.70 million, a P/E ratio of -1.01 and a beta of 1.89. The stock has a 50-day moving average price of $1.08 and a 200 day moving average price of $1.21.

Institutional Trading of Immunic

Large investors have recently added to or reduced their stakes in the business. Jane Street Group LLC lifted its stake in shares of Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares during the last quarter. HB Wealth Management LLC bought a new position in Immunic during the fourth quarter valued at about $81,000. State Street Corp lifted its position in shares of Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after buying an additional 11,642 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Immunic during the 3rd quarter valued at about $50,000. 51.82% of the stock is owned by institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.